RET, ROS1 and ALK fusions in lung cancer
- PMID: 22327623
- DOI: 10.1038/nm.2658
RET, ROS1 and ALK fusions in lung cancer
Abstract
Through an integrated molecular- and histopathology-based screening system, we performed a screening for fusions of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1, receptor tyrosine kinase (ROS1) in 1,529 lung cancers and identified 44 ALK-fusion-positive and 13 ROS1-fusion-positive adenocarcinomas, including for unidentified fusion partners for ROS1. In addition, we discovered previously unidentified kinase fusions that may be promising for molecular-targeted therapy, kinesin family member 5B (KIF5B)-ret proto-oncogene (RET) and coiled-coil domain containing 6 (CCDC6)-RET, in 14 adenocarcinomas. A multivariate analysis of 1,116 adenocarcinomas containing these 71 kinase-fusion-positive adenocarcinomas identified four independent factors that are indicators of poor prognosis: age ≥ 50 years, male sex, high pathological stage and negative kinase-fusion status.
Comment in
-
Genetics: Gene fusion power.Nat Rev Clin Oncol. 2012 Feb 28;9(4):188. doi: 10.1038/nrclinonc.2012.26. Nat Rev Clin Oncol. 2012. PMID: 22371133 No abstract available.
-
Chipping away at the lung cancer genome.Nat Med. 2012 Mar 6;18(3):349-51. doi: 10.1038/nm.2697. Nat Med. 2012. PMID: 22395697 No abstract available.
Similar articles
-
ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.Lung Cancer. 2014 May;84(2):121-6. doi: 10.1016/j.lungcan.2014.02.007. Epub 2014 Feb 19. Lung Cancer. 2014. PMID: 24629636
-
Decoding Tumor Phenotypes for ALK, ROS1, and RET Fusions in Lung Adenocarcinoma Using a Radiomics Approach.Medicine (Baltimore). 2015 Oct;94(41):e1753. doi: 10.1097/MD.0000000000001753. Medicine (Baltimore). 2015. PMID: 26469915 Free PMC article.
-
KIF5B-RET fusions in lung adenocarcinoma.Nat Med. 2012 Feb 12;18(3):375-7. doi: 10.1038/nm.2644. Nat Med. 2012. PMID: 22327624 Free PMC article.
-
Novel targets in non-small cell lung cancer: ROS1 and RET fusions.Oncologist. 2013;18(7):865-75. doi: 10.1634/theoncologist.2013-0095. Epub 2013 Jun 28. Oncologist. 2013. PMID: 23814043 Free PMC article. Review.
-
The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer.Mol Cancer. 2018 Feb 19;17(1):46. doi: 10.1186/s12943-018-0799-8. Mol Cancer. 2018. PMID: 29455670 Free PMC article. Review.
Cited by
-
LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive (RET+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC.Lung Cancer (Auckl). 2024 May 23;15:75-80. doi: 10.2147/LCTT.S460147. eCollection 2024. Lung Cancer (Auckl). 2024. PMID: 38807655 Free PMC article.
-
Insight into NSCLC through novel analysis of gene interactions and characteristics.Am J Clin Exp Immunol. 2024 Apr 25;13(2):58-67. doi: 10.62347/ANLV4963. eCollection 2024. Am J Clin Exp Immunol. 2024. PMID: 38765019 Free PMC article.
-
Expression patterns of HNF4α, TTF-1, and SMARCA4 in lung adenocarcinomas: impacts on clinicopathological and genetic features.Virchows Arch. 2024 May 6. doi: 10.1007/s00428-024-03816-6. Online ahead of print. Virchows Arch. 2024. PMID: 38710944
-
Current treatment and novel insights regarding ROS1-targeted therapy in malignant tumors.Cancer Med. 2024 Apr;13(8):e7201. doi: 10.1002/cam4.7201. Cancer Med. 2024. PMID: 38629293 Free PMC article. Review.
-
Lung adenocarcinoma patients with ROS1-rearranged tumors by sex and smoking intensity.Heliyon. 2024 Mar 16;10(7):e28285. doi: 10.1016/j.heliyon.2024.e28285. eCollection 2024 Apr 15. Heliyon. 2024. PMID: 38560203 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous